Imaging laboratory services provider Resonance Health announced that the U.S. Food and Drug Administration (FDA) has given the company permission to market its FerriScan R2-MRI device as an imaging companion diagnostic device in the use of Exjade pharmaceutical therapy.
FerriScan is a noninvasive test that helps physicians to identify patients with iron overload disorders. It can help determine which patients are appropriate candidates for nontransfusion-dependent thalassemia with Exjade (deferasirox), a Novartis drug that is used to remove excess iron in patients with genetic blood disorders.
FerriScan is also used to measure patients' response to the drug and help doctors determine when to discontinue therapy when safe levels of liver iron concentration are reached.
Resonance Health has 40 MRI center customers in the U.S. using FerriScan.
